Azita Hajhossein Talasaz

Azita Hajhossein Talasaz

Auto-generated profile, based on publicly available information

Azita Hajhossein Talasaz

Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 June 2023 in Current Hypertension Reports
Verified
Journal Article
Closed access
PDF file
SCStacey Cutrell
Stacey Cutrell
Ibrahim S. AlhomoudIbrahim S. Alhomoud
Ibrahim S. Alhomoud
AMAnurag Mehta
Anurag Mehta
ATAzita H. Talasaz
Azita H. Talasaz
BTBenjamin Van Tassell
Benjamin Van Tassell
DDDave L. Dixon
Dave L. Dixon

7 May 2008 in Journal of Applied Polymer Science
Verified
Journal Article
Closed access
PDF file
ATAzita H. H. Talasaz
Azita H. H. Talasaz
AGAli A. Ghahremankhani
Ali A. Ghahremankhani
SMShadi H. Moghadam
Shadi H. Moghadam
MRMazda Rad-Malekshahi
Mazda Rad-Malekshahi
FAFatemeh Atyabi
Fatemeh Atyabi
RDRassoul Dinarvand
Rassoul Dinarvand

26 July 2023 in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Verified
Journal Article
Open access
Ibrahim S. AlhomoudIbrahim S. Alhomoud
Ibrahim S. Alhomoud
ATAzita Talasaz
Azita Talasaz
AMAnurag Mehta
Anurag Mehta
MKMichael S. Kelly
Michael S. Kelly
ESEvan M. Sisson
Evan M. Sisson
DDDave L. Dixon
Dave L. Dixon
Lipoprotein(a), or Lp(a), is structurally like low‐density lipoprotein (LDL) but differs in that it contains glycoprotein apolipoprotein(a) [apo(a)]. Due to its prothrombotic and proinflammatory properties, Lp(a) is an independent risk factor for atherosclerotic cardiovascular disease (ASCVD) and aortic valve stenosis. Lp(a) levels are genetically determined, and it is estimated that 20%–25% of the global population has an Lp(a) level ≥50 mg/dL (or ≥125 nmol/L). Diet and lifestyle interventions have little to no effect on Lp(a) levels. Lipoprotein apheresis is the only approved treatment for elevated Lp(a) but is time‐intensive for the patient and only modestly effective. Pharmacological approaches to reduce Lp(a) levels and its associated risks are of significant interest; however, currently available lipid‐lowering therapies have limited effectiveness in reducing Lp(a) levels. Although statins are first‐line agents to reduce LDL cholesterol levels, they modestly increase Lp(a) levels and have not been shown to change Lp(a)‐mediated ASCVD risk. Alirocumab, evolocumab, and inclisiran reduce Lp(a) levels by 20‐25%, yet the clinical implications of this reduction for Lp(a)‐mediated ASCVD risk are uncertain. Niacin also lowers Lp(a) levels; however, its effectiveness in mitigating Lp(a)‐mediated ASCVD risk remains unclear, and its side effects have limited its utilization. Recommendations for when to screen and how to manage individuals with elevated Lp(a) vary widely between national and international guidelines and scientific statements. Three investigational compounds targeting Lp(a), including small interfering RNA (siRNA) agents (olpasiran, SLN360) and an antisense oligonucleotide (pelacarsen), are in various stages of development. These compounds block the translation of messenger RNA (mRNA) into apo(a), a key structural component of Lp(a), thereby substantially reducing Lp(a) synthesis in the liver. The purpose of this review is to describe current recommendations for screening and managing elevated Lp(a), describe the effects of currently available lipid‐lowering therapies on Lp(a) levels, and provide insight into emerging therapies targeting Lp(a).

28 July 2010 in Nephrology Dialysis Transplantation
Verified
Journal Article
Closed access
PDF file
ATAzita Hajhossein Talasaz
Azita Hajhossein Talasaz
MAMohammad-Reza Abbasi
Mohammad-Reza Abbasi
SASaeed Abkhiz
Saeed Abkhiz
SDSimin Dashti-Khavidaki
Simin Dashti-Khavidaki
Herbal medications are being progressively utilized all over the world. Nevertheless, herbal remedies are not without hazards and several cases of adverse reactions have been described. Tribulus terrestris is traditionally used because of its aphrodisiac and antiurolithiatic activities with almost complete inhibition of stone formation. We report a case of T. terrestris-induced hepatotoxicity, nephrotoxicity and neurotoxicity in an Iranian male patient who used the plant’s extract to prevent kidney stone formation. He presented with seizure and very high serum aminotransferases and creatinine after consuming herbal water for 2 days. Discontinuation of the herbal remedy resulted in improvement in symptoms and normalization of his liver enzymes.

1 January 2014 in Noise and Health
Verified
Journal Article
Open access
YLYones Lotfi
Yones Lotfi
AMAbdollah Moossavi
Abdollah Moossavi
EBEnayatollah Bakhshi
Enayatollah Bakhshi
ATAzitaHajhossein Talasaz
AzitaHajhossein Talasaz
AHAhmad Hoorzad
Ahmad Hoorzad
ADAfsaneh Doosti
Afsaneh Doosti
Previous studies revealed the role of antioxidant agents in prevention of noise induced hearing loss (NIHL). The aim of this study was to compare the protective effect of N-acetyl-cysteine (NAC) and ginseng on protection of NIHL in textile workers exposed to continuous noise in daily working. In this study, 48 participants were randomly allocated to three groups; Group I received NAC 1200 mg/day, Group II received ginseng 200 mg/day, and Group III (control group) received no supplement. Pure tone audiometry and high frequency audiometry were performed preshift before and after 14 days (on day 15). Linear regression analysis results showed reduced noise-induced temporary threshold shift (TTS) for NAC and ginseng groups at 4, 6 and 16 kHz (P < 0.001) in both ears. Furthermore, the protective effects were more prominent in NAC than ginseng. Our results show that NAC and ginseng can reduce noise induced TTS in workers exposed to occupational noise. Further studies are needed to prove antioxidants benefits in hearing conservation programs.

11 December 2011 in Clinical Research in Cardiology
Verified
Journal Article
Closed access
PDF file
HKHossein Khalili
Hossein Khalili
ATAzita Hajhossein Talasaz
Azita Hajhossein Talasaz
MSMojtaba Salarifar
Mojtaba Salarifar